SymbolBJDX
NameBLUEJAY DIAGNOSTICS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryMedical/Dental Instruments
Address360 MASSACHUSETTS AVENUE,SUITE 203, ACTON, Massachusetts, 01720, United States
Telephone+1 844 - 327-7078
Fax
Email
Websitehttps://www.bluejaydx.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK
Description

Bluejay Diagnostics Inc develops, manufactures and markets innovative clinical diagnostic products that improve the quality of medical diagnoses by developing Point-of-Care tests that provide convenience, timeliness, compliance and low cost to physicians and patients in areas where timeliness of the initial triage assessment has a high impact on course of treatment.

Additional info from NASDAQ:
Bluejay Diagnostics Inc develops, manufactures and markets innovative clinical diagnostic products that improve the quality of medical diagnoses by developing Point-of-Care tests that provide convenience, timeliness, compliance and low cost to physicians and patients in areas where timeliness of the initial triage assessment has a high impact on course of treatment.

2026-04-20 17:06

New Form PRE 14A - Bluejay Diagnostics, Inc. <b>Filed:</b> 2026-04-20 <b>AccNo:</b> 0001213900-26-045587 <b>Size:</b> 7 MB

Read more
2026-04-07 13:09

(85% Positive) BLUEJAY DIAGNOSTICS, INC. (BJDX) Announces Enrollment Update for outcomes Due to Patient Enrollment Issues, Regulatory Process

Read more
2026-04-07 10:30

Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial

Read more
2026-03-17 21:30

(99% Neutral) BLUEJAY DIAGNOSTICS, INC. (BJDX) Announces Business Combination

Read more
2026-03-16 10:07

(99% Neutral) BLUEJAY DIAGNOSTICS, INC. (BJDX) Files Form 8-K

Read more
2026-03-12 16:24

(99% Neutral) BLUEJAY DIAGNOSTICS, INC. (BJDX) Provides Update on intended for critical care conditions

Read more
2026-03-12 10:30

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

Read more
2026-03-11 09:55

New Form SCHEDULE 13D - Bluejay Diagnostics, Inc. <b>Filed:</b> 2026-03-11 <b>AccNo:</b> 0001213900-26-025973 <b>Size:</b> 60 KB

Read more
2026-03-11 09:13

New Form SCHEDULE 13D - Bluejay Diagnostics, Inc. <b>Filed:</b> 2026-03-11 <b>AccNo:</b> 0001213900-26-025962 <b>Size:</b> 60 KB

Read more
2026-03-11 07:40

New Form SCHEDULE 13D - Bluejay Diagnostics, Inc. <b>Filed:</b> 2026-03-11 <b>AccNo:</b> 0001213900-26-025920 <b>Size:</b> 60 KB

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT07425587 Multicenter Symphony™ IL-6 Monitoring Sepsis ED Pilot Study Sepsis, Septic Shock Not_Yet_Recruiting 2026-04-12 2026-12-30 ClinicalTrials.gov
NCT06654895 Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study Sepsis, Septic Shock Recruiting 2024-11-12 2026-08-30 ClinicalTrials.gov
NCT06181604 Multicenter Symphony IL-6 Monitoring Sepsis ICU Study Sepsis Completed 2024-01-12 2024-07-12 ClinicalTrials.gov
NCT05665153 Symphony IL-6 Study in Patients at Risk of Severe Sepsis Severe Sepsis Recruiting 2022-11-22 2024-11-21 ClinicalTrials.gov
NCT05048888 Symphony IL-6 Reference Range Study Sepsis Unknown 2021-08-31 2024-03-30 ClinicalTrials.gov
NCT05048927 Symphony IL-6 Cutoff Validation Study for Patients at Risk of Severe Sepsis Severe Sepsis Unknown 2021-08-31 2024-12-31 ClinicalTrials.gov
NCT05060250 Symphony IL-6 Cutoff Establishment Study for Patients at Risk of Severe Sepsis … Severe Sepsis Unknown 2021-08-31 2024-12-31 ClinicalTrials.gov
Total clinical trials: 7